Holen Sie sich die Stockscreener-App
0.00
100.00%
-8.61
Handel nachbörslich:
8.61
8.61
+
Schlusskurs vom Vortag:
$8.61
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$391.22M
Einnahmen:
$84.82M
Nettoeinkommen (Verlust:
$-21.43M
KGV:
0.00
EPS:
-0.49
Netto-Cashflow:
$-27.23M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$11.10
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Firmenname
Y Mabs Therapeutics Inc
Sektor
Branche
Telefon
646-885-8505
Adresse
202 CARNEGIE CENTER, PRINCETON, NY
Vergleichen Sie YMAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
0.00 | 391.22M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-11-18 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-28 | Eingeleitet | Truist | Buy |
| 2023-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-04-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-27 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-12-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-10-31 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-10-31 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-03 | Fortgesetzt | Guggenheim | Buy |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-11-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-23 | Fortgesetzt | Cowen | Outperform |
| 2021-03-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2020-05-01 | Eingeleitet | Janney | Buy |
| 2020-04-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-12-24 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Eingeleitet | Wedbush | Outperform |
| 2019-04-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-10-16 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Y Mabs Therapeutics Inc Aktie (YMAB) Neueste Nachrichten
Why Y mAbs Therapeutics Inc. stock is a must watch in 2025Swing Trade & Real-Time Buy Zone Alerts - moha.gov.vn
The Technical Signals Behind (YMAB) That Institutions Follow - news.stocktradersdaily.com
Is Y mAbs Therapeutics Inc. stock attractive for ETFsPortfolio Profit Report & Precise Trade Entry Recommendations - newser.com
Is Y mAbs Therapeutics Inc. stock trading at a premium valuationGap Down & Weekly Watchlist for Hot Stocks - newser.com
United States Brain Cancer Treatment Market in 2025 | Novel Drug - openPR.com
Why Y mAbs Therapeutics Inc. stock is considered a top pickEarnings Recap Summary & Fast Entry Momentum Trade Alerts - newser.com
Can Y mAbs Therapeutics Inc. stock withstand economic slowdownQuarterly Growth Report & Technical Buy Zone Confirmations - newser.com
Can Y mAbs Therapeutics Inc. stock continue upward trendDividend Hike & AI Optimized Trading Strategy Guides - newser.com
What’s next for Y mAbs Therapeutics Inc. stock priceQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com
How strong is Y mAbs Therapeutics Inc. stock balance sheet2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Is it too late to sell Y mAbs Therapeutics Inc.Market Activity Summary & Consistent Income Trade Recommendations - newser.com
Dr. Vignesh Rajah Appointed as SERB Pharmaceuticals’ Chief Medical Officer - GlobeNewswire
Is Y mAbs Therapeutics Inc. stock a dividend growth opportunityWeekly Profit Summary & Verified Entry Point Detection - newser.com
Does Y mAbs Therapeutics Inc. stock trade at a discount to peersM&A Rumor & Safe Entry Zone Identification - newser.com
Institutional scanner results for Y mAbs Therapeutics Inc.July 2025 Trends & Stepwise Trade Signal Implementation - newser.com
How Y mAbs Therapeutics Inc. stock trades before earningsMarket Performance Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Y mAbs Therapeutics Inc. stock a buy on dipsWeekly Gains Report & Verified Entry Point Detection - Fundação Cultural do Pará
Why analysts upgrade Y mAbs Therapeutics Inc. stockGap Up & Safe Entry Trade Signal Reports - newser.com
How geopolitical tensions affect Y mAbs Therapeutics Inc. stockJuly 2025 Patterns & Reliable Momentum Entry Alerts - newser.com
Precision Trading with Y-mabs Therapeutics Inc. (YMAB) Risk Zones - news.stocktradersdaily.com
Is Y mAbs Therapeutics Inc. stock reversal real or fake2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
How supply chain issues affect Y mAbs Therapeutics Inc. stock2025 Fundamental Recap & Capital Protection Trading Alerts - newser.com
How to forecast Y mAbs Therapeutics Inc. trends using time seriesTrade Performance Summary & Weekly High Potential Alerts - newser.com
Analyzing net buyer seller activity in Y mAbs Therapeutics Inc.July 2025 Momentum & Weekly Market Pulse Alerts - newser.com
Finanzdaten der Y Mabs Therapeutics Inc-Aktie (YMAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):